drugset / Trial / NCT00549523

A Controlled Study of the Safety and Efficacy of Lessertia Frutescens in HIV-infected South African Adults

NCT00549523

RandomizedParallel-groupDouble-blindSupportive care

Summary

The study is a 2-stage, double-blind, randomized, placebo-controlled study in which fifty-six HIV-positive subjects will be randomized into the first stage. Interim analysis to determine continuation to stage 2 will be performed to determine continuation after 8 subjects per arm have completed a 24-week dosing regimen. Primary objectives are to determine the safety of Lessertia frutescens when used by HIV-1 infected adults with early disease, and to document the impact of Lessertia frutescens on markers of HIV disease progression. Secondary objective is to determine the effect of Lessertia frutescens on quality of life in HIV-infected adults and length of infection.

Timeline

Start
2008-04
Primary completion
2012-01
Completion
2012-01

Drugs

EvaluationDrugModalityDoseRoute
Subject Aspirine Unknown 400 mg
Subject Aspirine Unknown 800 mg
Subject Aspirine Unknown 1200 mg